Global Radiopharmaceutical Theranostics Market
Global Radiopharmaceutical Theranostics Market

Radiopharmaceutical Theranostics Comprehensive Study by Type (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Lutetium (Lu) 177, Copper (Cu) 67, Others), Application (Oncology, Cardiology, Others), Route of Administration (Oral, Intravenous, Interstitial Route), Approach (Therapeutic (Rx), Companion Diagnostic (DX)) Players and Region - Global Market Outlook to 2026

Radiopharmaceutical Theranostics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 210 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Radiopharmaceutical Theranostics Market Scope
To treat or diagnose cancer, radioactive drugs can be administered orally, intravenously, or intramuscularly. These medications are administered in the presence of a specialist known as a radio pharmacist. When these radioactive drugs reach their target cell, they generate radiation, which kills the malignant cells. Radiopharmaceuticals for the treatment and diagnosis of thyroid, brain, bone, and lymphoma malignancies have previously been found. Radiopharmaceutical Therapy (RPT) is gaining popularity as a safe and effective way to treat a variety of cancers. Radiopharmaceuticals are utilized not just for treatment but also for diagnosis. Tracers are the medications that are utilized for diagnosis. When compared to radiation emitted by radiopharmaceuticals used for therapy, diagnostic radiopharmaceuticals emit less radiation. Radiopharmaceuticals are either single isotopes or kits including many isotopes.

The Radiopharmaceutical Theranostics market study is segmented by Type (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Lutetium (Lu) 177, Copper (Cu) 67 and Others), by Application (Oncology, Cardiology and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Radiopharmaceutical Theranostics market throughout the predicted period.

Nihon Medi-Physics (China), ITM Isotopen Technologien München AG (Germany), Advanced Accelerator Applications (France), Telix Pharmaceuticals (Australia), GE Healthcare (United States), Theragnostics Ltd. (United States), NuView Life Sciences (United States), Jubilant Pharma Limited (United States), Lantheus Holdings, Inc. (United States), Curium Pharma (United Kingdom), Bayer AG (Germany) and Clarity Pharmaceuticals (Australia) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Radiopharmaceutical Theranostics market by Type, Application and Region.

On the basis of geography, the market of Radiopharmaceutical Theranostics has been segmented into South America (Brazil, Argentina, Chile, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, Thailand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Spain, Sweden, Belgium, Poland, Norway, Austria, Russia, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 23rd Aug 2021 - Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI in radioguided surgery (RGS), On 15th June 2020 - Nihon Medi-Physics Co., Ltd (NMP), a leading radiopharmaceutical company in Japan and Global Medical Solutions, Ltd., (GMS), a leading-edge manufacturer and distributor of radiopharmaceuticals, diagnostic imaging products, equipment, devices, and services, announced today that they have signed an agreement for a strategic partnership in nuclear medicine markets in Asia and Oceania. and On 17th Feb 2021 - Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, has announces a research collaboration with Essen University Hospital to examine Theragnostics’ investigational agent THG-008 for PET imaging in a range of cancers.

In Europe, radiopharmaceutical compounds are considered a special group of medicines. Therefore, their preparation and use are regulated by a number of EU directives, regulations and rules that have been adopted by member states. and In United States, The NRC regulates the medical use of radioactive materials including regulations concerning radiation exposure. These regulations are promulgated via the Code of Federal Regulations.

Market Trend
  • The Increase in Application of Radioisotopes in the Healthcare Industry
  • Technological Advancements in the Diagnostics Sector

Market Drivers
  • Radiopharmaceuticals are Generating Major Oncology Deals Globally
  • Rise in Incidence and Prevalence of Target Conditions

Opportunities
  • Rise in Initiatives to Reduce the Demand-Supply Gap
  • Rising Use of Radiopharmaceuticals for the Diagnosis and Treatment of Chronic Disease

Restraints
  • Short Half-Life of Radiopharmaceuticals and High Equipment Prices


Key Target Audience
Healthcare Industry, Regulatory Bodies, Radiopharmaceutical Providers, Government Bodies and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Radiopharmaceutical Theranostics Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • Fluorine-18
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Others
By Application
  • Oncology
  • Cardiology
  • Others
By Route of Administration
  • Oral
  • Intravenous
  • Interstitial Route

By Approach
  • Therapeutic (Rx)
  • Companion Diagnostic (DX)

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Poland
    • Norway
    • Austria
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Radiopharmaceuticals are Generating Major Oncology Deals Globally
      • 3.2.2. Rise in Incidence and Prevalence of Target Conditions
    • 3.3. Market Trends
      • 3.3.1. The Increase in Application of Radioisotopes in the Healthcare Industry
      • 3.3.2. Technological Advancements in the Diagnostics Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiopharmaceutical Theranostics, by Type, Application, Route of Administration, Approach and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radiopharmaceutical Theranostics (Value)
      • 5.2.1. Global Radiopharmaceutical Theranostics by: Type (Value)
        • 5.2.1.1. Technetium-99
        • 5.2.1.2. Gallium-68
        • 5.2.1.3. Iodine-131
        • 5.2.1.4. Iodine-123
        • 5.2.1.5. Fluorine-18
        • 5.2.1.6. Lutetium (Lu) 177
        • 5.2.1.7. Copper (Cu) 67
        • 5.2.1.8. Others
      • 5.2.2. Global Radiopharmaceutical Theranostics by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Cardiology
        • 5.2.2.3. Others
      • 5.2.3. Global Radiopharmaceutical Theranostics by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Interstitial Route
      • 5.2.4. Global Radiopharmaceutical Theranostics by: Approach (Value)
        • 5.2.4.1. Therapeutic (Rx)
        • 5.2.4.2. Companion Diagnostic (DX)
      • 5.2.5. Global Radiopharmaceutical Theranostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Chile
          • 5.2.5.1.4. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Singapore
          • 5.2.5.2.6. Malaysia
          • 5.2.5.2.7. Thailand
          • 5.2.5.2.8. Australia
          • 5.2.5.2.9. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Spain
          • 5.2.5.3.7. Sweden
          • 5.2.5.3.8. Belgium
          • 5.2.5.3.9. Poland
          • 5.2.5.3.10. Norway
          • 5.2.5.3.11. Austria
          • 5.2.5.3.12. Russia
          • 5.2.5.3.13. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Radiopharmaceutical Theranostics (Price)
      • 5.3.1. Global Radiopharmaceutical Theranostics by: Type (Price)
  • 6. Radiopharmaceutical Theranostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Nihon Medi-Physics (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ITM Isotopen Technologien München AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Advanced Accelerator Applications (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Telix Pharmaceuticals (Australia)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Theragnostics Ltd. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NuView Life Sciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Jubilant Pharma Limited (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lantheus Holdings, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Curium Pharma (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bayer AG (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Clarity Pharmaceuticals (Australia)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Radiopharmaceutical Theranostics Sale, by Type, Application, Route of Administration, Approach and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radiopharmaceutical Theranostics (Value)
      • 7.2.1. Global Radiopharmaceutical Theranostics by: Type (Value)
        • 7.2.1.1. Technetium-99
        • 7.2.1.2. Gallium-68
        • 7.2.1.3. Iodine-131
        • 7.2.1.4. Iodine-123
        • 7.2.1.5. Fluorine-18
        • 7.2.1.6. Lutetium (Lu) 177
        • 7.2.1.7. Copper (Cu) 67
        • 7.2.1.8. Others
      • 7.2.2. Global Radiopharmaceutical Theranostics by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Cardiology
        • 7.2.2.3. Others
      • 7.2.3. Global Radiopharmaceutical Theranostics by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Interstitial Route
      • 7.2.4. Global Radiopharmaceutical Theranostics by: Approach (Value)
        • 7.2.4.1. Therapeutic (Rx)
        • 7.2.4.2. Companion Diagnostic (DX)
      • 7.2.5. Global Radiopharmaceutical Theranostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Chile
          • 7.2.5.1.4. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Singapore
          • 7.2.5.2.6. Malaysia
          • 7.2.5.2.7. Thailand
          • 7.2.5.2.8. Australia
          • 7.2.5.2.9. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Spain
          • 7.2.5.3.7. Sweden
          • 7.2.5.3.8. Belgium
          • 7.2.5.3.9. Poland
          • 7.2.5.3.10. Norway
          • 7.2.5.3.11. Austria
          • 7.2.5.3.12. Russia
          • 7.2.5.3.13. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Radiopharmaceutical Theranostics (Price)
      • 7.3.1. Global Radiopharmaceutical Theranostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiopharmaceutical Theranostics: by Type(USD Million)
  • Table 2. Radiopharmaceutical Theranostics Technetium-99 , by Region USD Million (2015-2020)
  • Table 3. Radiopharmaceutical Theranostics Gallium-68 , by Region USD Million (2015-2020)
  • Table 4. Radiopharmaceutical Theranostics Iodine-131 , by Region USD Million (2015-2020)
  • Table 5. Radiopharmaceutical Theranostics Iodine-123 , by Region USD Million (2015-2020)
  • Table 6. Radiopharmaceutical Theranostics Fluorine-18 , by Region USD Million (2015-2020)
  • Table 7. Radiopharmaceutical Theranostics Lutetium (Lu) 177 , by Region USD Million (2015-2020)
  • Table 8. Radiopharmaceutical Theranostics Copper (Cu) 67 , by Region USD Million (2015-2020)
  • Table 9. Radiopharmaceutical Theranostics Others , by Region USD Million (2015-2020)
  • Table 10. Radiopharmaceutical Theranostics: by Application(USD Million)
  • Table 11. Radiopharmaceutical Theranostics Oncology , by Region USD Million (2015-2020)
  • Table 12. Radiopharmaceutical Theranostics Cardiology , by Region USD Million (2015-2020)
  • Table 13. Radiopharmaceutical Theranostics Others , by Region USD Million (2015-2020)
  • Table 14. Radiopharmaceutical Theranostics: by Route of Administration(USD Million)
  • Table 15. Radiopharmaceutical Theranostics Oral , by Region USD Million (2015-2020)
  • Table 16. Radiopharmaceutical Theranostics Intravenous , by Region USD Million (2015-2020)
  • Table 17. Radiopharmaceutical Theranostics Interstitial Route , by Region USD Million (2015-2020)
  • Table 18. Radiopharmaceutical Theranostics: by Approach(USD Million)
  • Table 19. Radiopharmaceutical Theranostics Therapeutic (Rx) , by Region USD Million (2015-2020)
  • Table 20. Radiopharmaceutical Theranostics Companion Diagnostic (DX) , by Region USD Million (2015-2020)
  • Table 21. South America Radiopharmaceutical Theranostics, by Country USD Million (2015-2020)
  • Table 22. South America Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 23. South America Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 24. South America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 25. South America Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 26. Brazil Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 27. Brazil Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 28. Brazil Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 29. Brazil Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 30. Argentina Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 31. Argentina Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 32. Argentina Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 33. Argentina Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 34. Chile Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 35. Chile Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 36. Chile Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 37. Chile Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 38. Rest of South America Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 40. Rest of South America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 41. Rest of South America Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 42. Asia Pacific Radiopharmaceutical Theranostics, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 45. Asia Pacific Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 46. Asia Pacific Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 47. China Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 48. China Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 49. China Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 50. China Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 51. Japan Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 52. Japan Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 53. Japan Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 54. Japan Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 55. India Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 56. India Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 57. India Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 58. India Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 59. South Korea Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 60. South Korea Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 61. South Korea Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 62. South Korea Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 63. Singapore Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 64. Singapore Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 65. Singapore Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 66. Singapore Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 67. Malaysia Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 68. Malaysia Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 69. Malaysia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 70. Malaysia Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 71. Thailand Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 72. Thailand Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 73. Thailand Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 74. Thailand Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 75. Australia Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 76. Australia Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 77. Australia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 78. Australia Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 83. Europe Radiopharmaceutical Theranostics, by Country USD Million (2015-2020)
  • Table 84. Europe Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 85. Europe Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 86. Europe Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 87. Europe Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 88. Germany Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 89. Germany Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 90. Germany Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 91. Germany Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 92. France Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 93. France Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 94. France Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 95. France Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 96. Italy Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 97. Italy Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 98. Italy Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 99. Italy Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 100. United Kingdom Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 101. United Kingdom Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 102. United Kingdom Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 103. United Kingdom Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 104. Netherlands Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 105. Netherlands Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 106. Netherlands Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 107. Netherlands Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 108. Spain Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 109. Spain Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 110. Spain Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 111. Spain Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 112. Sweden Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 113. Sweden Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 114. Sweden Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 115. Sweden Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 116. Belgium Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 117. Belgium Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 118. Belgium Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 119. Belgium Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 120. Poland Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 121. Poland Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 122. Poland Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 123. Poland Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 124. Norway Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 125. Norway Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 126. Norway Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 127. Norway Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 128. Austria Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 129. Austria Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 130. Austria Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 131. Austria Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 132. Russia Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 133. Russia Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 134. Russia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 135. Russia Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 136. Rest of Europe Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 137. Rest of Europe Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 138. Rest of Europe Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 139. Rest of Europe Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 140. MEA Radiopharmaceutical Theranostics, by Country USD Million (2015-2020)
  • Table 141. MEA Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 142. MEA Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 143. MEA Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 144. MEA Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 145. Middle East Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 146. Middle East Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 147. Middle East Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 148. Middle East Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 149. Africa Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 150. Africa Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 151. Africa Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 152. Africa Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 153. North America Radiopharmaceutical Theranostics, by Country USD Million (2015-2020)
  • Table 154. North America Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 155. North America Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 156. North America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 157. North America Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 158. United States Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 159. United States Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 160. United States Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 161. United States Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 162. Canada Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 163. Canada Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 164. Canada Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 165. Canada Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 166. Mexico Radiopharmaceutical Theranostics, by Type USD Million (2015-2020)
  • Table 167. Mexico Radiopharmaceutical Theranostics, by Application USD Million (2015-2020)
  • Table 168. Mexico Radiopharmaceutical Theranostics, by Route of Administration USD Million (2015-2020)
  • Table 169. Mexico Radiopharmaceutical Theranostics, by Approach USD Million (2015-2020)
  • Table 170. Radiopharmaceutical Theranostics: by Type(USD/Units)
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Radiopharmaceutical Theranostics: by Type(USD Million)
  • Table 184. Radiopharmaceutical Theranostics Technetium-99 , by Region USD Million (2021-2026)
  • Table 185. Radiopharmaceutical Theranostics Gallium-68 , by Region USD Million (2021-2026)
  • Table 186. Radiopharmaceutical Theranostics Iodine-131 , by Region USD Million (2021-2026)
  • Table 187. Radiopharmaceutical Theranostics Iodine-123 , by Region USD Million (2021-2026)
  • Table 188. Radiopharmaceutical Theranostics Fluorine-18 , by Region USD Million (2021-2026)
  • Table 189. Radiopharmaceutical Theranostics Lutetium (Lu) 177 , by Region USD Million (2021-2026)
  • Table 190. Radiopharmaceutical Theranostics Copper (Cu) 67 , by Region USD Million (2021-2026)
  • Table 191. Radiopharmaceutical Theranostics Others , by Region USD Million (2021-2026)
  • Table 192. Radiopharmaceutical Theranostics: by Application(USD Million)
  • Table 193. Radiopharmaceutical Theranostics Oncology , by Region USD Million (2021-2026)
  • Table 194. Radiopharmaceutical Theranostics Cardiology , by Region USD Million (2021-2026)
  • Table 195. Radiopharmaceutical Theranostics Others , by Region USD Million (2021-2026)
  • Table 196. Radiopharmaceutical Theranostics: by Route of Administration(USD Million)
  • Table 197. Radiopharmaceutical Theranostics Oral , by Region USD Million (2021-2026)
  • Table 198. Radiopharmaceutical Theranostics Intravenous , by Region USD Million (2021-2026)
  • Table 199. Radiopharmaceutical Theranostics Interstitial Route , by Region USD Million (2021-2026)
  • Table 200. Radiopharmaceutical Theranostics: by Approach(USD Million)
  • Table 201. Radiopharmaceutical Theranostics Therapeutic (Rx) , by Region USD Million (2021-2026)
  • Table 202. Radiopharmaceutical Theranostics Companion Diagnostic (DX) , by Region USD Million (2021-2026)
  • Table 203. South America Radiopharmaceutical Theranostics, by Country USD Million (2021-2026)
  • Table 204. South America Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 205. South America Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 206. South America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 207. South America Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 208. Brazil Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 209. Brazil Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 210. Brazil Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 211. Brazil Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 212. Argentina Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 213. Argentina Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 214. Argentina Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 215. Argentina Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 216. Chile Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 217. Chile Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 218. Chile Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 219. Chile Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 220. Rest of South America Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 221. Rest of South America Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 222. Rest of South America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 223. Rest of South America Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 224. Asia Pacific Radiopharmaceutical Theranostics, by Country USD Million (2021-2026)
  • Table 225. Asia Pacific Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 226. Asia Pacific Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 227. Asia Pacific Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 228. Asia Pacific Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 229. China Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 230. China Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 231. China Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 232. China Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 233. Japan Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 234. Japan Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 235. Japan Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 236. Japan Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 237. India Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 238. India Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 239. India Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 240. India Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 241. South Korea Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 242. South Korea Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 243. South Korea Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 244. South Korea Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 245. Singapore Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 246. Singapore Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 247. Singapore Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 248. Singapore Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 249. Malaysia Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 250. Malaysia Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 251. Malaysia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 252. Malaysia Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 253. Thailand Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 254. Thailand Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 255. Thailand Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 256. Thailand Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 257. Australia Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 258. Australia Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 259. Australia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 260. Australia Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 261. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 262. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 263. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 264. Rest of Asia-Pacific Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 265. Europe Radiopharmaceutical Theranostics, by Country USD Million (2021-2026)
  • Table 266. Europe Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 267. Europe Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 268. Europe Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 269. Europe Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 270. Germany Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 271. Germany Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 272. Germany Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 273. Germany Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 274. France Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 275. France Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 276. France Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 277. France Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 278. Italy Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 279. Italy Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 280. Italy Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 281. Italy Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 282. United Kingdom Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 283. United Kingdom Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 284. United Kingdom Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 285. United Kingdom Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 286. Netherlands Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 287. Netherlands Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 288. Netherlands Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 289. Netherlands Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 290. Spain Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 291. Spain Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 292. Spain Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 293. Spain Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 294. Sweden Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 295. Sweden Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 296. Sweden Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 297. Sweden Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 298. Belgium Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 299. Belgium Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 300. Belgium Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 301. Belgium Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 302. Poland Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 303. Poland Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 304. Poland Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 305. Poland Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 306. Norway Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 307. Norway Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 308. Norway Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 309. Norway Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 310. Austria Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 311. Austria Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 312. Austria Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 313. Austria Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 314. Russia Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 315. Russia Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 316. Russia Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 317. Russia Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 318. Rest of Europe Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 319. Rest of Europe Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 320. Rest of Europe Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 321. Rest of Europe Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 322. MEA Radiopharmaceutical Theranostics, by Country USD Million (2021-2026)
  • Table 323. MEA Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 324. MEA Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 325. MEA Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 326. MEA Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 327. Middle East Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 328. Middle East Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 329. Middle East Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 330. Middle East Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 331. Africa Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 332. Africa Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 333. Africa Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 334. Africa Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 335. North America Radiopharmaceutical Theranostics, by Country USD Million (2021-2026)
  • Table 336. North America Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 337. North America Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 338. North America Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 339. North America Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 340. United States Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 341. United States Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 342. United States Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 343. United States Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 344. Canada Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 345. Canada Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 346. Canada Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 347. Canada Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 348. Mexico Radiopharmaceutical Theranostics, by Type USD Million (2021-2026)
  • Table 349. Mexico Radiopharmaceutical Theranostics, by Application USD Million (2021-2026)
  • Table 350. Mexico Radiopharmaceutical Theranostics, by Route of Administration USD Million (2021-2026)
  • Table 351. Mexico Radiopharmaceutical Theranostics, by Approach USD Million (2021-2026)
  • Table 352. Radiopharmaceutical Theranostics: by Type(USD/Units)
  • Table 353. Research Programs/Design for This Report
  • Table 354. Key Data Information from Secondary Sources
  • Table 355. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiopharmaceutical Theranostics: by Type USD Million (2015-2020)
  • Figure 5. Global Radiopharmaceutical Theranostics: by Application USD Million (2015-2020)
  • Figure 6. Global Radiopharmaceutical Theranostics: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Radiopharmaceutical Theranostics: by Approach USD Million (2015-2020)
  • Figure 8. South America Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 9. Asia Pacific Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 10. Europe Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 11. MEA Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 12. North America Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 13. Global Radiopharmaceutical Theranostics: by Type USD/Units (2015-2020)
  • Figure 14. Global Radiopharmaceutical Theranostics share by Players 2020 (%)
  • Figure 15. Global Radiopharmaceutical Theranostics share by Players (Top 3) 2020(%)
  • Figure 16. Global Radiopharmaceutical Theranostics share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Nihon Medi-Physics (China) Revenue, Net Income and Gross profit
  • Figure 19. Nihon Medi-Physics (China) Revenue: by Geography 2020
  • Figure 20. ITM Isotopen Technologien München AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. ITM Isotopen Technologien München AG (Germany) Revenue: by Geography 2020
  • Figure 22. Advanced Accelerator Applications (France) Revenue, Net Income and Gross profit
  • Figure 23. Advanced Accelerator Applications (France) Revenue: by Geography 2020
  • Figure 24. Telix Pharmaceuticals (Australia) Revenue, Net Income and Gross profit
  • Figure 25. Telix Pharmaceuticals (Australia) Revenue: by Geography 2020
  • Figure 26. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 27. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 28. Theragnostics Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Theragnostics Ltd. (United States) Revenue: by Geography 2020
  • Figure 30. NuView Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 31. NuView Life Sciences (United States) Revenue: by Geography 2020
  • Figure 32. Jubilant Pharma Limited (United States) Revenue, Net Income and Gross profit
  • Figure 33. Jubilant Pharma Limited (United States) Revenue: by Geography 2020
  • Figure 34. Lantheus Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Lantheus Holdings, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Curium Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Curium Pharma (United Kingdom) Revenue: by Geography 2020
  • Figure 38. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 40. Clarity Pharmaceuticals (Australia) Revenue, Net Income and Gross profit
  • Figure 41. Clarity Pharmaceuticals (Australia) Revenue: by Geography 2020
  • Figure 42. Global Radiopharmaceutical Theranostics: by Type USD Million (2021-2026)
  • Figure 43. Global Radiopharmaceutical Theranostics: by Application USD Million (2021-2026)
  • Figure 44. Global Radiopharmaceutical Theranostics: by Route of Administration USD Million (2021-2026)
  • Figure 45. Global Radiopharmaceutical Theranostics: by Approach USD Million (2021-2026)
  • Figure 46. South America Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 47. Asia Pacific Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 48. Europe Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 49. MEA Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 50. North America Radiopharmaceutical Theranostics Share (%), by Country
  • Figure 51. Global Radiopharmaceutical Theranostics: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Nihon Medi-Physics (China)
  • ITM Isotopen Technologien München AG (Germany)
  • Advanced Accelerator Applications (France)
  • Telix Pharmaceuticals (Australia)
  • GE Healthcare (United States)
  • Theragnostics Ltd. (United States)
  • NuView Life Sciences (United States)
  • Jubilant Pharma Limited (United States)
  • Lantheus Holdings, Inc. (United States)
  • Curium Pharma (United Kingdom)
  • Bayer AG (Germany)
  • Clarity Pharmaceuticals (Australia)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation